Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening

Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.

Trial Details

NCT ID
NCT06512311
Phase
NA
Sponsor
Medical University of Vienna
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • CBMed Drug Screening Plattform
Locations (sample)
  • Vienna, State of Vienna, Austria|48.20849,16.37208

Key Eligibility Criteria

  • ECOG performance status 0-2
  • Newly diagnosed glioblastoma, IDH wildtype - according to the 2021 WHO classification of Tumors of the Central Nervous System
  • MGMT promotor unmethylated per local investigator
  • Tissue available for drug screening (successful PDC establishment from surgical material)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →